efalizumab, etanercept, and infliximab). In a recent Japanese Society for Psoriasis Research analysis of 28,628 cases, herbal medicines (14.5%) ranked highest among systemic therapies used.

Trials of new agents—such as alefacept, efalizumab, and tumour necrosis factor α (TNFα) inhibitors such as etanercept and infliximab—have demonstrated that patients’ quality of life clearly improves ...

This study of the efficacy and cost-effectiveness of moderate to severe psoriasis treatments compared phototherapy, oral systemic agents, and biologics from a managed health care systems ...

Guidance on the use of capecitabine and tegafur with uracil for metastatic colorectal cancer TA61 27 May 2003 27 May 2003 Guidance on the use of drugs for early thrombolysis in the treatment of acute ...